| Outcome Measures: |
Primary: Changes from baseline in HbA1c (%), To evaluate changes in HbA1c (%) from baseline after initiation of therapy with exenatide once-weekly in patients with different renal functions or age classes, as referred to basal insulin initiators of the same subgroups., one year post-index|Changes from baseline in weight (kg), To evaluate changes in weight (kg) from baseline after initiation of therapy with exenatide once-weekly in patients with different renal functions or age classes, as referred to basal insulin initiators of the same subgroups., one year post-index | Secondary: Changes from baseline in eGFR, Changes in eGFR after initiation of therapy with exenatide once-weekly in patients with different renal functions or age classes, as referred to basal insulin initiators of the same subgroups., one year post-index|Frequency of Hypoglycemia, Frequency of episodes of hypoglycaemia after initiation of therapy with exenatide once-weekly in patients with different renal functions or age classes, as referred to basal insulin initiators of the same subgroups., one year post-index|Frequency of Nausea, Frequency of episodes of nausea after initiation of therapy with exenatide once-weekly in patients with different renal functions or age classes, as referred to basal insulin initiators of the same subgroups., one year post-index|Frequency of Vomiting, Frequency of episodes of vomiting after initiation of therapy with exenatide once-weekly in patients with different renal functions or age classes, as referred to basal insulin initiators of the same subgroups., one year post-index
|
